{"id":26894,"date":"2024-06-01T12:00:00","date_gmt":"2024-06-01T12:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4428151_CN28151_0"},"modified":"2024-06-01T12:00:00","modified_gmt":"2024-06-01T12:00:00","slug":"immunocan-launches-innovative-alpaca-derived-nanobody-discovery-platform-immualpaca-mouse","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=26894","title":{"rendered":"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse"},"content":{"rendered":"\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 1, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca<sup>&reg;<\/sup> mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced&nbsp;by alpaca IGH-VDJ genes in-situ.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p style=\"TEXT-ALIGN: center; WIDTH: 100%\"> <a href=\"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.html\" target=\"_blank\" rel=\"nofollow noopener\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600\" title=\"\" alt=\"\" \/> <\/a> <br \/><span><\/span><\/p>\n<\/p><\/div>\n<p>In 1993, naturally occurring heavy-chain-only antibodies (HCAbs) were discovered. Compared to the heavy chain variable regions of traditional antibodies, the variable domain of heavy&nbsp;chain&nbsp;of HCAbs (V<sub>H<\/sub>H) from camelids (also known as nanobodies)&nbsp;have four aliphatic amino acid residues in the FR2 region replaced by hydrophilic amino acids. &nbsp;This substitution confers greater stability in the absence of a light chain. Nanobodies are the smallest antigen-binding fragments found in nature.&nbsp;With a molecular weight of only 15 kDa, nanobodies offer great flexibility and are easy to&nbsp;use as components for constructing therapeutic molecules in innovative format such as multivalent and multispecific antibody molecular structures.&nbsp;Over the past 20 years, extensive research and development achievements have&nbsp;demonstrated the significant value of nanobodies in clinical therapeutic use.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Brand<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Disease<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Target<br \/><\/b><\/span><span class=\"prnews_span\"><b>Antigen<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Company<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Approval <br \/>Status<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Cablivi<sup>&reg;<\/sup> <br \/>(caplacizumab-<br \/>yhdp)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Acquired thrombotic <br \/>thrombocytopenicpurpura<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Von Willebrand <br \/>factor<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Ablynx NV<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Approved <br \/>(USA, EU)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Carvykti<sup>&reg;<\/sup> (Ciltacabtagene<br \/>autoleucel)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Refractory\/relapsed<br \/>multiple myeloma<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">B-cell <br \/>maturation<br \/>antigen<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Legend Biotech\/<br \/><\/span><span class=\"prnews_span\">Janssen Biotech, Inc<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Approved <br \/>(USA, EU)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Nanozora<sup>&reg;<\/sup> <br \/>(Ozoralizumab)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Rheumatoid arthritis<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Tumor necrosis<br \/>factor-alpha<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Ablynx NV\/<br \/><\/span><span class=\"prnews_span\">Taisho Pharmaceuticals Holdings\/<br \/><\/span><span class=\"prnews_span\">EddingPharm<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Approved <br \/>(Japan)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Enweida<sup>&reg;<\/sup> <br \/>(Envonolimab)<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">MSI-H or dMMR <br \/>adult&nbsp;advanced solid <br \/>tumors<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Programmed <br \/>death-ligand 1<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Alphamab Oncology\/ 3D <br \/>Medicines, Inc.\/<\/span><span class=\"prnews_span\"> <\/span><span class=\"prnews_span\">Simcere<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Approved <br \/>(China)<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&nbsp;<\/p>\n<p>Currently, nanobodies can be obtained mainly through three approaches: camelid immune libraries, na&iuml;ve camelid libraries, and fully synthetic libraries. Among these, camelid immune libraries are the most widely used for screening. However, due to the large size and low reproductive rate of camelids, the required antigen amount for immunization is high and the immunization strategy employed in one discovery campaign is limited. Besides, lacking standardized breeding and experimental facilities further impacted their reliability and performance. A novel approach is needed to keep up with the increasing demand for nanobody-based drug discovery.<\/p>\n<p>Immunocan has developed the innovative camelid-derived nanobody discovery platform, ImmuAlpaca<sup>&reg;<\/sup> mouse, through patented MASIRT<sup>&reg;<\/sup> technology. This platform&nbsp;enables nanobody discovery using robust strategy and methods from standard mice model. MASIRT<sup>&reg;<\/sup> technology involves replacing the IGH-VDJ&nbsp;(Variable, Diversity and Joining segments of immunoglobulin heavy locus)&nbsp;genes in the mouse genome with camelid-derived IGH-VDJ genes in-situ. Immunization of ImmuAlpaca<sup>&reg;<\/sup> mouse can generate highly diversified nanobody libraries. This allows for the use of diversified immunization and antibody screening strategies common in mouse models, significantly improving the performance of nanobody molecule discovery.<\/p>\n<p>&nbsp;<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\"><\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\"><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>ImmuAlpaca&reg; Mouse<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Camelids<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Reduction in Antigen Usage<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">ug per individual<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">mg per individual<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Immunization Strategy Diversity<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Multiple groups of <\/span><span class=\"prnews_span\">mouses<\/span><span class=\"prnews_span\"> with <br \/>different antigen forms and<br \/>immunization plans<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Single strategy for one camelid<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Screening Strategy Diversity<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Hybridoma screening, single B<br \/>cell screening, phage, and yeast<br \/>library screening<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Phage and yeast library screening<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&nbsp;<\/p>\n<p>In addition to the ImmuAlpaca<sup>&reg;<\/sup> mouse, Immunocan has already developed the ImmuMab Heavy&reg; mouse, generating fully human heavy-chain-only antibodies and is constructing the ImmuHeavy&reg; rabbit, generating rabbit heavy-chain-only antibodies.&nbsp;Using these models will expand the sequence space for nanobody discovery at multiple level. By leveraging the advantages of antibody sequences and structures from different species, exploring more target epitopes and therapeutic mechanisms will be easier.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\"><\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>ImmuAlpaca&reg;<br \/><\/b><\/span><span class=\"prnews_span\"><b>Mouse<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>ImmuMab Heavy&reg;<br \/><\/b><\/span><span class=\"prnews_span\"><b>Mouse<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>ImmuHeavy&reg;<br \/><\/b><\/span><span class=\"prnews_span\"><b>Rabbit<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Molecular Origin<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Camelid<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Human<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Rabbit<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Molecular Feature Advantages<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Good hydrophilicity,<br \/>strong affinity, high <br \/>stability<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">No need for humanization<\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">High affinity, high diversity<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&nbsp;<\/p>\n<p>Immunocan will continue to innovate with multi-species antibody discovery platforms&nbsp;to accelerate&nbsp;the development of&nbsp;novel therapeutics and&nbsp;drugs. Immunocan is looking forward to introducing its innovative antibody discovery platforms to global research partners and seek collaboration to bring safer and more effective therapeutic products to patients worldwide.<\/p>\n<p><b>About the Massive-fragment Across Species In-situ Replacement Technology <i>(MASIRT&reg;)<br \/><\/i><\/b>Immunocan&#8217;s core technology features one-step gene replacement at Mb scale between two species.&nbsp; Its advantageous genome-engineering efficiency enables rapid construction of multiple specialized antibody discovery platforms, including mice generating fully human antibodies or alpaca antibodies and rabbits generating fully human antibodies (under construction).<\/p>\n<p><b>About <i>Immuno<\/i><i>c<\/i><i>an<br \/><\/i><\/b>Immunocan was founded in 2020 and specializes in using gene editing technology to replace immunoglobulin variable region genes in various animals, resulting in genetically engineered animals capable of producing fully human antibodies and other innovative modalities. The company is committed to offering cutting-edge antibody discovery platforms to worldwide drug research partners, with the goal of developing safer and more effective treatments for human diseases.<\/p>\n<p><b>Media Contact<\/b><br \/>Youyang Shen<br \/><a href=\"mailto:shenyouyang@immunocan.com\" target=\"_blank\" rel=\"nofollow noopener\">shenyouyang@immunocan.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, June 1, 2024 \/PRNewswire\/ &#8212; Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca&reg; mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced&nbsp;by alpaca IGH-VDJ genes in-situ. In 1993, naturally occurring heavy-chain-only antibodies (HCAbs) were discovered. Compared to the heavy chain variable regions of traditional antibodies, [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-26894","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=26894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse - My Blog\" \/>\n<meta property=\"og:description\" content=\"BOSTON, June 1, 2024 \/PRNewswire\/ &#8212; Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca&reg; mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced&nbsp;by alpaca IGH-VDJ genes in-situ. In 1993, naturally occurring heavy-chain-only antibodies (HCAbs) were discovered. Compared to the heavy chain variable regions of traditional antibodies, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=26894\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-01T12:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse\",\"datePublished\":\"2024-06-01T12:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894\"},\"wordCount\":771,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2426865\\\/image_5030155_28772283.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894\",\"name\":\"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2426865\\\/image_5030155_28772283.jpg?p=medium600\",\"datePublished\":\"2024-06-01T12:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2426865\\\/image_5030155_28772283.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2426865\\\/image_5030155_28772283.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=26894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=26894","og_locale":"en_US","og_type":"article","og_title":"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse - My Blog","og_description":"BOSTON, June 1, 2024 \/PRNewswire\/ &#8212; Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca&reg; mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced&nbsp;by alpaca IGH-VDJ genes in-situ. In 1993, naturally occurring heavy-chain-only antibodies (HCAbs) were discovered. Compared to the heavy chain variable regions of traditional antibodies, [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=26894","og_site_name":"My Blog","article_published_time":"2024-06-01T12:00:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=26894#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=26894"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse","datePublished":"2024-06-01T12:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=26894"},"wordCount":771,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=26894#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=26894","url":"https:\/\/transmediavictoria.net.au\/?p=26894","name":"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=26894#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=26894#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600","datePublished":"2024-06-01T12:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=26894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=26894"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=26894#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2426865\/image_5030155_28772283.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=26894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/26894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26894"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/26894\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}